fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

Completed · Phase 1

Conditions studied: Social Anxiety Disorder

In brief

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

Key facts

Study ID

NCT00332046

Run by

GlaxoSmithKline

People needed

57

Starts

2006-01-01

Last updated by the study team

2008-10-16

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary diagnosis of Social Anxiety Disorder.
• Willing to restrict alcohol to a limited intake.

You may not qualify if…

• History of schizophrenia, schizoaffective disorder or a bipolar disorder.
• Left-handed.
• Suffer from claustrophobia.
• Any reason why subject could not go into the fMRI, for example have metal implants.

Where it is running

• GSK Investigational Site — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.